Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Spondyloarthritis family · A closer look at PsA

PsA: heart and metabolic health

Good PsA care includes the heart, blood vessels, glucose metabolism and liver, as well as joints and skin. This is part of routine care, not a judgement about your habits.

Olga Goodman, MD · Sources checked 27 September 2026

Chapter 10 of 21

The essentials

Discuss cardiovascular and metabolic risk alongside inflammation control. Blood pressure, cholesterol, glucose, smoking and weight need their own plan; feeling better in the joints does not replace these checks.

Risk is individual, not a prediction of your future

PsA often coexists with obesity and cardiometabolic conditions. Inflammation and conventional risk factors can both matter. Your actual risk depends on the full picture, including age, blood pressure, cholesterol, diabetes, smoking and personal or family cardiovascular history. Comorbidities also influence medicine selection. 8

Ask who will coordinate prevention and how the rheumatology and primary care teams will share results. Do not assume that a normal inflammation marker means low cardiovascular risk, or that PsA means a heart problem is inevitable.

Turn screening into a follow-up plan

Bring previous results and dates rather than requesting every test again. Agree which measurements are needed, what the results mean and who will follow up. The interval and targets depend on findings, medicines, age and local guidance; there is no single schedule for everyone.

Turn screening into a follow-up plan
AreaA useful question
Blood pressureWhat do my readings mean, and would home measurements help?
Cholesterol and overall cardiovascular riskWhen were my lipids checked, and do I need a prevention discussion or treatment?
GlucoseDo my history and risk factors indicate glucose or HbA1c testing?
Weight and nutritionWhat support is appropriate and what outcome matters beyond the scale?
LiverDo metabolic risk, alcohol or medicines indicate liver tests or further assessment? An abnormal result needs interpretation, not an automatic assumption about its cause.

Make weight care practical and respectful

If excess weight is affecting health, discuss an achievable plan that considers pain, sleep, appetite, medicines, finances and food access. Support can include nutrition care, adapted activity and, when appropriate, treatment for obesity. Weight change is not a prerequisite for receiving effective PsA treatment. 3, 9

Judge progress through function and metabolic health as well as weight. A dietitian can help preserve adequate nutrition during weight loss. Unintentional weight loss, poor appetite or difficulty maintaining intake needs its own assessment. Avoid a crash diet copied from a research protocol.

Choose the next useful action

Stopping smoking, sustainable activity and a balanced eating pattern support wider health. If you smoke, ask about cessation support and medicines rather than relying on willpower alone. Check how alcohol fits with your liver health and prescribed treatment. 3, 9

Before adding pain medicines, supplements or weight-loss products, review them with your clinician or pharmacist. Some medicines can affect blood pressure, kidney function, glucose or liver tests; monitoring depends on the actual drug and your circumstances. Bring your full list to both primary care and rheumatology visits. 8

Heart, sugar, liver: PsA’s travel companions — Free after registration →

Smoking and alcohol: an honest chat — Free after registration →

Go deeper

What the one year results add

The one-year TOGETHER-PsA results support treating obesity alongside psoriatic arthritis. Adding tirzepatide to ixekizumab improved arthritis outcomes in selected adults with excess weight. Tirzepatide does not replace arthritis treatment. Discuss eligibility, side effects and access; the study does not show that everyone with PsA needs this combination. 14, 15

This was an open-label study, and the week-52 comparisons were exploratory. Arthritis and weight outcomes still need separate assessment.

Questions for your visit

  1. Who is coordinating my cardiovascular and metabolic prevention?
  2. Which results need action now, and when should they be rechecked?
  3. Would structured obesity or smoking-cessation care help me?
  4. Do my comorbidities affect the choice or monitoring of my PsA medicine?

When to seek urgent help

A painful red eye, light sensitivity or a sudden change in vision needs urgent assessment. A newly hot, swollen joint, especially with fever or feeling unwell, also needs prompt assessment.

Sources & evidence notes

Sources checked 27 September 2026

Recommendations, individual studies and sponsor announcements have different evidential weight. The text identifies these distinctions.

  1. NIAMS. Psoriatic arthritis: treatment and steps to take.
  2. Coates LC et al. GRAPPA treatment recommendations 2021. Nat Rev Rheumatol. 2022.
  3. Gwinnutt JM et al. EULAR lifestyle recommendations 2021. Ann Rheum Dis. 2023.
  4. TOGETHER PsA investigators. Ixekizumab plus tirzepatide at 52 weeks. ACR 2026; randomized open-label phase 3b; week-52 testing not multiplicity controlled.
  5. Coates et al.. TOGETHER PsA early disease control and week 36. ACR 2026 abstract 2297; assessor-blinded trial and composite primary endpoint.

Educational information for patients and caregivers. This personal publication is not the clinic portal and does not provide individual diagnosis or treatment. Discuss medication changes with your own care team.

© 2026 Olga Goodman, MD · A RheumaView publication. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Cardiovascular diseasePsoriasisPsoriatic arthritisQuality of lifeSpondyloarthritis